X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
oncology (40) 40
index medicus (31) 31
female (29) 29
male (26) 26
middle aged (26) 26
aged (22) 22
adult (21) 21
cancer (20) 20
chemotherapy (19) 19
respiratory system (19) 19
mesothelioma (17) 17
cisplatin (16) 16
lung neoplasms - pathology (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
hematology, oncology and palliative medicine (12) 12
lung neoplasms - drug therapy (12) 12
analysis (10) 10
cisplatin - administration & dosage (10) 10
lung neoplasms - genetics (10) 10
malignant pleural mesothelioma (10) 10
pulmonary/respiratory (10) 10
research (10) 10
care and treatment (9) 9
cell line, tumor (9) 9
lung cancer (9) 9
lung cancer, non-small cell (9) 9
mesothelioma - metabolism (9) 9
surgery (9) 9
tumors (9) 9
aged, 80 and over (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
expression (8) 8
lung neoplasms - metabolism (8) 8
neoplasm staging (8) 8
treatment outcome (8) 8
610 medicine & health (7) 7
antineoplastic agents - therapeutic use (7) 7
clinic for oncology (7) 7
combined modality therapy (7) 7
disease-free survival (7) 7
health aspects (7) 7
induction chemotherapy (7) 7
mesothelioma - pathology (7) 7
prognosis (7) 7
apoptosis (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
extrapleural pneumonectomy (6) 6
immunohistochemistry (6) 6
lung neoplasms - therapy (6) 6
pneumonectomy (6) 6
radiotherapy (6) 6
randomized-trial (6) 6
survival (6) 6
survival rate (6) 6
antineoplastic agents - pharmacology (5) 5
biomarkers, tumor - metabolism (5) 5
cancer research (5) 5
carcinoma (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
cisplatin - pharmacology (5) 5
clinical trials (5) 5
critical care medicine (5) 5
deoxycytidine - analogs & derivatives (5) 5
gefitinib (5) 5
inhibition (5) 5
lung neoplasms - mortality (5) 5
mesothelioma - drug therapy (5) 5
pemetrexed (5) 5
phase-ii trial (5) 5
time factors (5) 5
tumor cells, cultured (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
apoptosis - drug effects (4) 4
blotting, western (4) 4
cancer therapies (4) 4
carcinoma, small cell - pathology (4) 4
cell proliferation (4) 4
cell proliferation - drug effects (4) 4
chemotherapy, adjuvant (4) 4
clinical trials as topic (4) 4
cohort studies (4) 4
disease progression (4) 4
dna-binding proteins - genetics (4) 4
dna-binding proteins - metabolism (4) 4
genetic aspects (4) 4
growth (4) 4
growth-factor receptor (4) 4
guanine - analogs & derivatives (4) 4
lung-cancer (4) 4
medical research (4) 4
mesothelioma - genetics (4) 4
mesothelioma - therapy (4) 4
neoadjuvant therapy (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
phosphorylation (4) 4
pleural neoplasms - metabolism (4) 4
pleural neoplasms - therapy (4) 4
polymerase chain reaction (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 5, pp. 435 - 444
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9998, pp. 1049 - 1056
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 8, pp. 785 - 793
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2012, Volume 12, Issue 1, pp. 571 - 571
Background: Optimizing the safety and efficacy of standard chemotherapeutic agents such as cisplatin (CDDP) is of clinical relevance. Serum starvation in vitro... 
AMPK | cisplatin therapy | ATM/Chk2/p53 signaling | Serum starvation | short-term food starvation (STS) | PROTEIN-KINASE | DNA-DAMAGE | TUMOR-CELLS | H2AX PHOSPHORYLATION | ONCOGENE | ONCOLOGY | GROWTH | MESOTHELIOMA | ATM ACTIVATION | STRESS | CARCINOMA | Cell Cycle - genetics | Protein Kinases - genetics | Humans | Tumor Suppressor Protein p53 - genetics | Starvation - metabolism | DNA-Binding Proteins - metabolism | Tumor Suppressor Proteins - genetics | Cell Cycle Proteins - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein-Serine-Threonine Kinases - metabolism | Cell Line | Tumor Suppressor Proteins - metabolism | HCT116 Cells | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Tumor Suppressor Protein p53 - metabolism | Signal Transduction - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | DNA-Binding Proteins - genetics | Enzyme Activation - drug effects | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Cell Line, Tumor | Checkpoint Kinase 2 | Cell Proliferation - drug effects | Mice | DNA Damage | Cell Cycle - drug effects | Physiological aspects | Genetic aspects | Cellular signal transduction | Research | Cisplatin | Cancer cells | Antimitotic agents | Starvation | Chemotherapy | Lung cancer | Comparative analysis | Antineoplastic agents | Tumor proteins | Cancer
Journal Article
Journal Article
Molecular Cancer, ISSN 1476-4598, 05/2014, Volume 13, Issue 1, pp. 119 - 119
Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer with short overall survival. Long non-coding RNAs (lncRNA) are a class of RNAs more... 
Malignant pleural mesothelioma | RNA FISH | Cell cycle length | Long non-coding RNA | Quiescence | CORTISOL STIMULATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-PROLIFERATION | CANCER | CULTURE | GROWTH-HORMONE PRODUCTION | ARREST | GLUCOCORTICOID-RECEPTOR | INHIBITION | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | EXPRESSION | Cell Cycle - genetics | RNA, Small Interfering - genetics | Cell Proliferation | Luciferases - metabolism | Membrane Glycoproteins - metabolism | Mesothelioma - pathology | TOR Serine-Threonine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Gene Expression Regulation, Neoplastic | Hedgehog Proteins - metabolism | Ki-67 Antigen - metabolism | Lung Neoplasms - pathology | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Luciferases - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | TOR Serine-Threonine Kinases - genetics | Hedgehog Proteins - genetics | Genes, Reporter | Lung Neoplasms - genetics | Promoter Regions, Genetic | Signal Transduction | Mesothelioma - genetics | RNA, Long Noncoding - genetics | Membrane Glycoproteins - genetics | Phosphatidylinositol 3-Kinases - genetics | Mesothelioma - metabolism | Ki-67 Antigen - genetics | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Primary Cell Culture | RNA, Long Noncoding - antagonists & inhibitors | RNA, Long Noncoding - metabolism | RNA, Small Interfering - metabolism | Immunohistochemistry | Studies | Thoracic surgery | Statistical analysis | Microscopy | Laboratories | Scanners | Gene expression | Binding sites | Tumors
Journal Article
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2015, Volume 149, Issue 6, pp. 1539 - 1547.e1
Objectives Survival and response to platinum-based induction chemotherapy are heterogeneous among patients with malignant pleural mesothelioma. The aim of the... 
Cardiothoracic Surgery | multimodality treatment | RRM1 | prognostic factor | mesothelioma | ERCC1 | Prognostic factor | Mesothelioma | Multimodality treatment | 10.1 | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | GEMCITABINE | CELL LUNG-CANCER | TRIAL | CISPLATIN | RESPIRATORY SYSTEM | EXTRAPLEURAL PNEUMONECTOMY | RESISTANCE | DNA-REPAIR | BIOPSIES | multi-modality treatment | ERCC1 EXPRESSION | Immunohistochemistry | Multivariate Analysis | Predictive Value of Tests | Mesothelioma - pathology | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Tissue Array Analysis | Humans | Middle Aged | DNA-Binding Proteins - analysis | Lung Neoplasms - pathology | Male | Mesothelioma - mortality | Pneumonectomy | Time Factors | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Pleural Neoplasms - pathology | Mesothelioma - therapy | Lung Neoplasms - enzymology | Biomarkers, Tumor - analysis | Deoxycytidine - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Lung Neoplasms - therapy | Pleural Neoplasms - mortality | Pemetrexed | Pleural Neoplasms - therapy | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mesothelioma - enzymology | Glutamates - administration & dosage | Pleural Neoplasms - enzymology | Endonucleases - analysis | Platinum Compounds - administration & dosage | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Tumor Suppressor Proteins - analysis | Chemotherapy | Surgery | Cancer
Journal Article